[go: up one dir, main page]

WO2007011647A3 - Inhibitors of mitotic kinesin ksp - Google Patents

Inhibitors of mitotic kinesin ksp Download PDF

Info

Publication number
WO2007011647A3
WO2007011647A3 PCT/US2006/027217 US2006027217W WO2007011647A3 WO 2007011647 A3 WO2007011647 A3 WO 2007011647A3 US 2006027217 W US2006027217 W US 2006027217W WO 2007011647 A3 WO2007011647 A3 WO 2007011647A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
mitotic kinesin
kinesin ksp
ksp
mitotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/027217
Other languages
French (fr)
Other versions
WO2007011647A2 (en
Inventor
Anthony B Pinkerton
Robert L David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalypsys Inc
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of WO2007011647A2 publication Critical patent/WO2007011647A2/en
Publication of WO2007011647A3 publication Critical patent/WO2007011647A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds and methods useful as inhibitors of KSP for the treatment or prevention of cellular proliferative diseases.
PCT/US2006/027217 2005-07-15 2006-07-13 Inhibitors of mitotic kinesin ksp Ceased WO2007011647A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69952105P 2005-07-15 2005-07-15
US60/699,521 2005-07-15
US76161306P 2006-01-24 2006-01-24
US60/761,613 2006-01-24

Publications (2)

Publication Number Publication Date
WO2007011647A2 WO2007011647A2 (en) 2007-01-25
WO2007011647A3 true WO2007011647A3 (en) 2007-05-18

Family

ID=37622033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/027217 Ceased WO2007011647A2 (en) 2005-07-15 2006-07-13 Inhibitors of mitotic kinesin ksp

Country Status (1)

Country Link
WO (1) WO2007011647A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079973A2 (en) * 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006002236A1 (en) * 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
WO2006031607A2 (en) * 2004-09-13 2006-03-23 Merck & Co., Inc. A method of treating cancer
WO2006068933A2 (en) * 2004-12-21 2006-06-29 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006098961A2 (en) * 2005-03-09 2006-09-21 Schering Corporation Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity
WO2006098962A1 (en) * 2005-03-09 2006-09-21 Schering Corporation Compounds for inhibiting ksp kinesin activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079973A2 (en) * 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006002236A1 (en) * 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
WO2006031607A2 (en) * 2004-09-13 2006-03-23 Merck & Co., Inc. A method of treating cancer
WO2006068933A2 (en) * 2004-12-21 2006-06-29 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006098961A2 (en) * 2005-03-09 2006-09-21 Schering Corporation Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity
WO2006098962A1 (en) * 2005-03-09 2006-09-21 Schering Corporation Compounds for inhibiting ksp kinesin activity

Also Published As

Publication number Publication date
WO2007011647A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2007011760A3 (en) Inhibitors of mitotic kinesin
WO2007011759A3 (en) Inhibitors of mitotic kinesin
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2005117867A3 (en) Monocyclic heterocycles as kinase inhibitors
WO2007025090A3 (en) Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2006023651A3 (en) Extended treatment of multiple sclerosis
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2008033562A3 (en) Kinase inhibitor compounds
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2007121125A3 (en) Hcv inhibitors
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
WO2006078574A3 (en) Mitotic kinesin inhibitors
WO2006068933A3 (en) Mitotic kinesin inhibitors
TNSN08496A1 (en) Aminothiazoles and their uses
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
WO2005060654A3 (en) Mitotic kinesin inhibitors
WO2006086358A3 (en) Mitotic kinesin inhibitors
WO2006031348A3 (en) Mitotic kinesin inhibitors
WO2006078598A3 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06787160

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06787160

Country of ref document: EP

Kind code of ref document: A2